Health in your pocket
IppocraTech, is an Italian startup with an unfair advantage:
its AI technology is able to measure
THE 5 VITAL SIGNS
defined by WHO to assess a person’s health status
Simultaneously
Certified as medical device CE Class IIa
A user-friendly technology for
the Patient/End User
Other Advantages
- Algorithms integrable with third-party devices
- Software API for third-party integration
- Telemedicine platform integrated in the technology
- Very competitive price vs other medical devices
Why 5 vital parameters?
Respiration Rate
Heart Rate
Blood Saturation
Blood Pressure
Temperature
Arterial Hypertension
Level of diffusion
30-45% of the adult population (half of these do not know they are affected because they do not show symptoms)
Consequences
stroke, heart attack,
heart failure, kidney failureBlood pressure
using IppocraTech technology, a medical doctor can quickly check the patient's blood pressure trend and immediately detect if it is dangerously increasing
Atrial Fibrillation
Level of diffusion
30% of the population over 65 years old
Using IppocraTech technology
a medical doctor can diagnose a atrial fibrillation looking at ECG trace
Pulmonary Embolism
Level of diffusion
acute pulmonary artery occlusion is fatal in 70% of cases and can affect even young subjects
Using IppocraTech technology
a medical doctor can detect a possible pulmonary embolism in time thanks to the simultaneous reporting of the heart rate increase, the blood pressure fall, and the saturation fall
Chronic Obstructive Pulmonary Disease
Level of diffusion
550 million people. It is one of the widespread chronic respiratory disease, with a significant burden on the quality of life
Using IppocraTech technology
a medical doctor can detect a possible acute exacerbation of COPD in time thanks to the simultaneous reporting of the respiratory rate increase, the saturation fall, and the heart rate increase
Cancer
Using IppocraTech technology
a medical doctor can remotely monitor chemotherapy's effects on cancer patients (e.g., cardio-toxicity development)
Sources: 2018 ESC/ESH Guidelines for the management of arterial hypertension; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS); The global impact of Aspergillus infection on COPD, Emily E. Hammond, Charles S. McDonald, Jørgen Vestbo, and David W. Denning, BMP Pulmonary Medicine, 2020.
Clinical trials
UNIMORE
